secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001493152-25-013100
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve SKNY acquisition; combined enterprise value >$60M
----------------------------------------------------------------------

- SKNY will contribute $5M in cash or assets to MIRA at closing.
- Moore Financial Consulting valued SKNY at $30.5M and MIRA at $30M; combined >$60M.
- Directors elected: Erez Aminov, Matthew Whalen, Matthew Del Giudice, Denil Nanji Shekhat, Edward MacPherson.
- 2022 Omnibus Incentive Plan amended: shares increased from 5M to 8M, option repricing allowed.
- Transaction expected to close shortly, subject to customary closing conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225013100/0001493152-25-013100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225013100/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-013100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer